Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 075 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 075 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride dissociates to provide potassium ions, which are essential for maintenance of intracellular tonicity, nerve impulse transmission, contraction of cardiac, skeletal, and smooth muscle, and normal renal function. Dextrose provides caloric support and is metabolized via glycolysis and the Krebs cycle. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid volume and osmolality.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion. Dose is determined by electrolyte requirements and fluid status. Typical maintenance: 1-2 mEq/kg/day potassium chloride, 100-200 mL/kg/day dextrose 10% (providing 10-20 g/kg/day dextrose), and sodium chloride 0.45% (providing 0.45 g/kg/day sodium chloride). Administer at a rate not exceeding 10 mEq/h potassium chloride via peripheral line; central line may allow up to 20 mEq/h with continuous cardiac monitoring.
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateNone Documented
None Documented
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Potassium: not classically defined due to rapid cellular redistribution; terminal half-life for administered K+ is approximately 1-1.5 hours in healthy individuals. Dextrose: distribution half-life ~5-10 min; elimination depends on utilization and renal function. Sodium chloride: no defined half-life; excreted based on body needs.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Potassium: primarily renal excretion (>90%) via distal tubular secretion; negligible biliary or fecal. Dextrose: metabolized to CO2 and water; renal excretion of unchanged glucose negligible (glycosuria if threshold exceeded). Sodium chloride: renal excretion (Na+ and Cl-) with homeostasis; extrarenal losses minimal under normal conditions.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."